Oncothermia Journal
Volume 11



Download the full journal


Szasz A, Szasz O (2014) Case reports made with Oncothermia I. Oncothermia Journal 11:9-70

The list of the cases

Local

Type

Number of cases

  1. Bone

Bone metastases

1

Case 1

  1. Brain

Glioblastoma multiform
Astrocytoma
Brain metastases

6
6
1

Case 1 - 6
Case 7 – 12
Case 13

  1. Breast

Mammary carcinoma

5

Case 1 – 5

  1. Colorectal

Colon adenocarcinoma
Rectum carcinoma
Ulcerative transverse colon

1
2
1

Case 1
Case 2 – 3
Case 4

  1. Esophagus

Esophagus carcinoma

3

Case 1 – 3

  1. Gastric

Stomach carcinoma

4

Case 1 - 4

  1. Head + Neck

Tongue cancer
Tumor of sinus sphenoidalis

2
1

Case 1 – 2
Case 3

  1. Lymphoma

Non-Hodgkin Lymphoma

2

Case 1 – 2

  1. Liver

Cholangio-cellular carcinoma
Hepatic metastasis
Intrahepatic bile-duct carcinoma
Liver metastasis

1
1
1
10

Case 1
Case 2
Case 3
Case 4 – 13

  1. Lung

Bronchial carcinoma
Lung adenocarcinoma
Lung cancer
Lung metastasis
Non-small cell lung cancer
Small-cell lung cancer

6
3
4
3
4
2

Case 1 – 6
Case 7 – 9
Case 10 – 13
Case 14 – 16
Case 17 – 20
Case 21 – 22

  1. Pelvis

Cystadenocarcinoma
Cervix uterus carcinoma
Prostate carcinoma
Vagina polypoid tumor

1
4
1
1

Case 1
Case 2 – 5
Case 6
Case 7

  1. Urinary

Ureter carcinoma
Uroepithelium carcinoma

1
1

Case 1
Case 2

Total:

79


Yu-Shan Wang, Chao-Chun Chang, Yi-Chun Hung, Yi-Ying Huang, Ren-Hong Wu, Gabor Andocs, Yuk Wah Tsang, Kwan-Hwa Chi (2014) Different cytotoxic effect from different hyperthermia devices. Comparison of the Oncotherm-Labehy and the Thermotron RF-8 in an in vitro model. Oncothermia Journal 11:91-91

“Purpose: Deep heating electro-hypertermia methods are a promising cancer treatment modalities used to enhance conventional treatment. This could be achieved through radiofrequency field on 8 and 13.56 MHz by Thermotron RF-8 and Oncotherm-Labehy, respectively. However, the difference cytotoxic effect between different hyperthermia devices has never been evaluated. ….”


Taesig Jeung, Sun Young Ma, Ji Hoon Choi, Jae Sang Yu, Sangwook Lim, Oliver Szasz (2014) Modulated electro-hyperthermia applied as monotherapy for various cases having no other options. Oncothermia Journal 11:92-92

“Introduction: Cancer has limited curative possibilities in high-line treatments. Our objective study modulated electro-hyperthermia (mEHT) [2], as monotherapy, treating patients in advanced stages, when other possibilities was not applicable. ….”


Ji Hoon Choi, Sun Young M, Jae Sang Yu, Sangwook Lim, Tae Sig Jeung, Oliver Szasz (2014) Modulated electro-hyperthermia therapy combined with gold-standard therapies for primary, recurrent and metastatic sarcinomas. Oncothermia Journal 11:93-93

“Introduction: After surgery sarcoma has high incidence of local recurrence and distant metastases. It is mostly resistant on radiotherapy and shows only limited response to chemotherapy. Presently a study showed the efficacy of conventional hyperthermia for sarcoma cases [1]. Our objective study modulated electro-hyperthermia (mEHT) [2], combined with conventional therapies for various sarcomas. …”


Yasunori Akutsu, Yutaka Tamura, Kentaro Murakami, Wei Qin, Xin Hu, Akiko Suganami, Hiroshi Suito, Hisahiro Matsubara (2014) Can modulated electro-hyperthermia (mEHT) elicit immune reaction? – From basic and clinical research. Oncothermia Journal 11:94-94

“Background: Previously, we investigated whether radiotherapy can elicit immunoreaction which, we think, is mediated by abscopal effect. On the other hand, modulated electro-hyperthermia (mEHT) was developed and it is still unknown whether mEHT can elicit immunoreaction or not. Therefore, we conducted a basic and clinical research. …”


Sergey Roussakow (2014) Dialectics of hyperthermia and oncothermia: development through negation. Oncothermia Journal 11:95-95

“Electromagnetic therapy in terms of biological effect is initially 'a unity of opposites', namely of the specific, non-thermal effect of alternating electromagnetic fields and inevitable nonspecific heating, each having its own efficiency. First, 'the struggle of the opposites' led to negation of any role of non-thermal effects and absolutisation of the thermal component, resulted in the formation of so-called 'thermal dogma' in 30s. Temperature oncological hyperthermia based on the 'thermal dogma' failed in terms of implementation after 50 years of development. At the same time, theory and practice of non-thermal effects of alternating electromagnetic fields were developing. …”


Joon H Kim (2014) Mixed Response to TS-1 and Oncothermia in a Esophageal Cancer Patient with Lung Metastases: Case Report. Oncothermia Journal 11:95-95

“Introduction: Management of patients suffering from esophageal cancer with lung metastasis remains challenging in routine clinical practice. Oncothermia has recently been applied as novel therapeutic option for metastatic or recurrent esophageal cancer patients. We report a case of esophageal cancer patient with showing a restricted response in the Oncothermia application field during TS-1 systemic chemotherapy. …”


Hee Bum Yang, Mi Young Shin, Yun Han Lee, Chang Geol Lee (2014) Suppression of Human Cancer Cell Growth in Vitro by Oncothermia. Oncothermia Journal 11:96-96

“Purpose: In the present study, we investigated the potential of oncothermia (electro·hyperthermia) for an alternative therapeutic option of pan-human cancer. Materials and methods: To address this issue, we applied oncothermic heating (42 centigrade 1 hour, three times with a two- or three-day interval) to various human cancer cell lines such as A549 Oung cancer), HepG2 Oiver cancer), MDA-MB231 (breast cancer) and A172 & U-87MG (brain cancer), and then examined for cancer cell phenotypic changes. Cell growth was analyzed by an MTT assay or microscopic observation in 3 days of the third oncothermic heating, and apoptosis was estimated in 24h of the third treatment by ELISA for the detection of denatured ssDNA only formed during apoptotic progression. In addition, the changes in apoptotic cell population was assessed by flow cytometry. The expression of heat shock protein 70 (HSP70), which is known for a typical marker of heat resistance, was determined by quantitative real-time PCR. …”


Andras Szasz (2014) Oncothermia in Clinical Practice. Oncothermia Journal 11:97-97

“Background: Oncothermia clinical applications have been started in the 1990s in Germany. It is a German medical method based on a Hungarian invention which reached the approval in the European Union in 1998, and is still rapidly spreading all over the world. Oncothermia is nowadays present in 30+ countries, and 100,000+ treatments are provided per year. Together with the 'classical' EHY2000 locoregional device, the intraluminal EHY1000 and the multilocal EHY3000 series are popular on the market. The marketed products are completed with devices for in-vitro and in-vivo laboratory research, as well as with numerous accessories helping the oncothermia applications in practice. …”


Andras Szasz (2014) Does the success of hyperthermia depend on the heating-method? Oncothermia Journal 11:98-98

“Background: Oncothermia has a quarter-century history [1]. It was started by typical invasive solution (ECT, electro-cancer-therapy) and tried also invasive interstitial technology; even systemic heating was also in the production range. However, the non-invasive loco-regional (EHY2000 series) and the multilocal (EHY3000 series) products, together with the intraluminar application (EHY1000 series) became popular among professionals. Why has Oncotherm tried so many forms of synergy of electric and thermal effects? Because it had historically the same frustration as hyperthermia had in general with the start of A d'Arsonval through W. Coley or HI. Robins to H. LeVeen. My objective is to discuss the challenges and show the possible solutions of present status of oncological hyperthermia. …”


Gabor Andocs, Csaba Kovago, Nora Meggyeshazi, Oliver Szasz (2014) Oncothermia treatment induced immunogenic cancer cell death – New possibilities for therapeutic cancer vaccine. Oncothermia Journal 11:99-99

“Introduction: Oncothermia method (OTM) is a long time applied tumor treatment modality in the human clinical practice. Experimental results showed that OTM can effectively and selectively destroy the tumor tissue, but recent investigations revealed some unusual immunological aspect of OTM. The immunogenic characteristics of immunogenic cell death (ICD) are mainly mediated by damage-associated molecular patterns (DAMPs). We summarize our results regarding the OTM induced ICD in Study I. Based on these observations we hypothesized a method for in vivo, in situ, personalized tumor vaccination. To prove this theory we designed an other study (Study II.) using immunocompetent animal model. …”


Yu-Shan Wang, Yi-Chun Huang, Rui-Chi Huang, Mau-Shin Chi, Gabor Andocs, Yuk-Wah Tsang, Andras Szasz, Kwan-Hwa Chi (2014) The Systemic Efficacy of Combined Immunotherapy with Oncothermia and Intratumoral Injection of Dendritic Cells. Oncothermia Journal 11:100-100

“Purpose: Oncothermia is a significant and definite technical development in the hyperthermia field, using capacitive (impedance) coupling of 13.56MHz amplitude-modulated radiofrequency energy on the tumor site. As a result, turning local apoptosis effect into a systemic anti-tumor immune response is possible. Oncothermia method is capable of turning tumor microenvironment into an immunological more favorable environment. In this study, our aim was to enhance the therapeutic effect of dendritic cells (DCs) immunotherapy after Oncothermia treatment. …”


Oliver Szasz (2014) Challenges and perspectives of hyperthermia in oncology. Oncothermia Journal 11:101-101

“Background: Hyperthermia could not find its established place among the 'gold standards' of the oncotherapies until now. We have to understand better the basic effects induced thermally and/or non-thermally. Challenges: Dosing of hyperthermia is completely different from other therapies. In case of hyperthermia the dose connected to tumortemperature which is indefinite, spread by blood and surrounding tissues. There are numerous electromagnetic hyperthermia methods distinguished by the kind of the fields, frequencies, heated volume, and conjunction with other methods, etc. The technical challenge of the deep-heating and the surface overheating is serious, and by the surface heat-sink blocks applying energy as dose parameter. …”


Doo Yun Lee, Joon Suk Park, Chang Young Lim, Gun Leei, Eun Seoul Byun, Seung Ju Choi, Seok Jin Haam, Sung Soo Lee (2014) The Outcomes of Oncothermia with Chemotherapy for Far Advanced Lung Cancer. Oncothermia Journal 11:102-102

“Nowadays, most oncologists face the challenge of ideal therapies without side-effects for cancer treatment. Conventional Hyperthermia can not achieve curative higher temperature in deep-seated tumors. Oncothermia can raise temperature and changing pH environment around the tumor. Combination of oncothermia with chemotherapy may enhance chemo-sensitivity, induce higher drug concentration around and inside the tumor, resulting tumor destruction. We report the outcomes of treatment by oncothermia with chemotherapy for 3 far advanced lung cancer in CHA Bundang Medical Center and Gangnam Severace Hospital.”


Yun Hwan Kim, Woong Ju, Seung Cheol Kim (2014) Conversion of chemo-sensitivity by adding electro-hyperthermia in recurrent endometrial cancer: A Case Report. Oncothermia Journal 11:102-102

“Modulated electro-hyperthermia is an emerging complementary treatment option for refractory solid tumor. Early experience suggests that it may have advantages over conventional hyperthermia with exceeding efficacy, and less complication. Herein, we describe a case of chemo-resistant, recurrent endometrial cancer patient; a successful conversion of chemo-sensitivity by the combination of electro-hyperthermia. On the way of chemotherapy for relapsed endometrial cancer, elevation of CA-125 marker frequently means chemo-resistance of the tumor. In this case, we observed sudden decrease of tumor marker during refractory chemotherapy by adding electrohyperthermia. The gross lesion was finally disappeared completely on CT scan and PET imaging, and the serum CA-125 marker was also normalized and maintained. Adding electro-hyperthermia could be a good treatment option even for the chemo-resistant endometrial cancer by converting chemo-sensitivity.”


Oncotherm